Tercica Will Transition Patients On iPlex To Increlex Following Insmed Patent Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
Insmed will no longer provide iPlex growth hormone to short stature patients but can pursue development of the drug in certain other indications.
You may also be interested in...
White Paper Is Actually Branded Promotion, FDA Tells Ipsen
Warning letter states that when only one drug (Increlex in this case) provides a therapy discussed in promotional materials, they "effectively promote" the drug even if they do not mention it by name.
White Paper Is Actually Branded Promotion, FDA Tells Ipsen
Warning letter states that when only one drug (Increlex in this case) provides a therapy discussed in promotional materials, they "effectively promote" the drug even if they do not mention it by name.
Merck Adds Biosimilar Capabilities, Insmed Gets Fresh Start In $130M Deal
A virtually broke biotech finds itself flush with cash while a major pharma's recently launched follow-on biologics play now enjoys an expanded pipeline and increased research and manufacturing capabilities - that's the outcome of a transaction labeled "a win/win for both parties" by Insmed CEO Geoffrey Allan